Lexaria Bioscience - LEXX Company profit before taxes, interest and amortization
Lexaria Bioscience (LEXX) reports a base operating result before depreciation that demonstrates efficiency dynamics, with the value stabilizing at 0.00. Margin resilience is supported by DehydraTECH patents, which create a significant barrier to entry for competitors. Growth potential is linked to the implementation of delivery systems for anti-obesity drugs; however, international licensing is complicated by geopolitical tensions and regulatory disputes regarding intellectual property protection.
Summary analytical data breakdowns for Lexaria Bioscience Corp. (LEXX)
- market value and analyst target forecast:
- issuer market value details:
- issuer book value statistics:
- business debt structure and liquidity details:
All Debt to Shareholders' Equity Ratio Lexaria Bioscience|LEXX - Long-Term Debt to Equity|Short-Term Debt to Equity Lexaria Bioscience Corp|LEXX - Company Aggregate Debts|Debts to Book Value Lexaria Bioscience|LEXX - Company Long-Term Liabilities|Company Short-Term Indebtedness Lexaria Bioscience|Quick Ratio lexariabioscience.com
- earnings and market ratios statistics:
LEXX - Company Net Income|Expected Net Income Lexaria Bioscience|LEXX - P/E Multiple|Market Cap to Projected Earnings Lexaria Bioscience Corp|LEXX - PEG Multiple|EV/EBITDA Multiple Lexaria Bioscience|LEXX - Operating profit before deduction of amortization|Earnings per share for the trailing year Lexaria Bioscience|LEXX - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months lexariabioscience.com|LEXX - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Lexaria Bioscience
Summary company analytics:Lexaria Bioscience
For Lexaria Bioscience (LEXX), which utilizes outsourced manufacturing and strict biosafety regulations, the EBITDA trend visualization reflects the actual cash flow from the commercialization of bioavailability technologies. This indicator excludes non-cash depreciation and amortization charges, allowing investors to assess the actual operational efficiency of the business; an upward curve confirms the company's ability to generate liquidity, while a decline signals a critical increase in costs.
Competitor analysis for Lexaria Bioscience
Haleon Corp (HLN) - Profit before interest, taxes and amortization|KVUE: Operating profit before deduction of amortization|veronapharma.com - Company profit before taxes, interest and amortization|MENS: Operating profit EBITDA|Ligand Pharmaceuticals Incorporated - Income before deduction of interest, taxes and amortization|AMRX (Amneal Pharmaceuticals Inc) - Operating profit EBITDA|Profit before interest, taxes and amortization Perrigo Corp PRGO|Profit before payment of interest, taxes and amortization Alvotech (ALVO)|LQDA (liquidia.com) - Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Galapagos GLPG|ANI Pharmaceuticals Inc - Profit before payment of interest, taxes and amortization|MannKind Corp. - Operating profit EBITDA|Profit before interest, taxes and amortization Amphastar Corp|PCRX (Pacira BioSciences) - Operating profit before deduction of amortization|Operating profit before amortization SPRY|TBPH (Theravance Biopharma, Inc.) - Operating profit EBITDA|Operating profit EBITDA Aquestive Therapeutics Inc|Profit before payment of interest, taxes and amortization scPharmaceuticals Inc. (SCPH)|TECX (tectonictx.com) - Income before deduction of interest, taxes and amortization|Operating profit EBITDA TNXP (Tonix Pharmaceuticals)|Operating income before deduction of amortization SXT Pharmaceuticals (SXTC)|Eupraxia Pharma - Operating profit EBITDA|BHST - Operating profit EBITDA|EXOZ (Invizyne Technologies, Inc.) - Operating profit before deduction of amortization|Oramed Pharmaceuticals Inc. - Income before deduction of interest, taxes and amortization|ENTX (Entera Bio Ltd) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization HYFT|Operating profit EBITDA ABVC|Operating income before deduction of amortization Cumberland Pharmaceuticals Inc|Profit before payment of interest, taxes and amortization Quantum BioPharma Limited QNTM|FibroGen Corporation (FGEN) - Profit before interest, taxes and amortization|TELO - Profit before payment of interest, taxes and amortization|Operating income before deduction of amortization Rani Therapeutics RANI|SNYR: Operating profit EBITDA|Operating profit before deduction of amortization Rallybio|PULM (Pulmatrix Corp) - Operating profit EBITDA|Pheton (PTHL) - Operating income before deduction of amortization|Operating profit EBITDA APM|LYRA - Profit before interest, taxes and amortization|Profit before payment of interest, taxes and amortization Impact BioMedical IBO|TNFA: Operating profit before amortization|cbdMD Corp - Operating profit EBITDA|PainReform Corp (PRFX) - Operating profit before deduction of amortization|CYTO: Operating profit EBITDA|Profit before interest, taxes and amortization lipella.com (LIPO)|Profit before payment of interest, taxes and amortization OptiNose|Profit before payment of interest, taxes and amortization PIRS|Operating profit EBITDA PROC|PTPI - Profit before interest, taxes and amortization|Qilian International - Operating profit before deduction of amortization|SLRN: Operating profit before amortization|TFFP: Operating profit before deduction of amortization
